{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:38:31Z","timestamp":1784896711800,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"am","delay-in-days":272,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"National Institutes of Health Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW010313"],"award-info":[{"award-number":["D43TW010313"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI069511-16"],"award-info":[{"award-number":["UM1AI069511-16"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN 75N93022C00009"],"award-info":[{"award-number":["HHSN 75N93022C00009"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009750","name":"University of Rochester Medical Center","doi-asserted-by":"publisher","award":["UM1AI069511-16"],"award-info":[{"award-number":["UM1AI069511-16"]}],"id":[{"id":"10.13039\/100009750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jchromb.2025.124774","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:10:08Z","timestamp":1756336208000},"page":"124774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["LC-MS\/MS method for quantifying the HIV-1 broadly neutralizing antibody PGT 121.414.LS in human serum"],"prefix":"10.1016","volume":"1266","author":[{"given":"Connor E.","family":"Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Zemaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"DiFrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-8511","authenticated-orcid":false,"given":"Troy D.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124774_bb0005","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg. Microbes Infections"},{"key":"10.1016\/j.jchromb.2025.124774_bb0010","first-page":"412","article-title":"Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies","volume":"37","author":"Kwong","year":"2012","journal-title":"Immunity (Cambridge, Mass.)"},{"key":"10.1016\/j.jchromb.2025.124774_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature\u2019s pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jchromb.2025.124774_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11904-016-0299-7","article-title":"Broadly neutralizing antibodies for HIV eradication","volume":"13","author":"Stephenson","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.jchromb.2025.124774_bb0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2025.124774_bb0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jchromb.2025.124774_bb0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jchromb.2025.124774_bb0040","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review","volume":"223","author":"Mahomed","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jchromb.2025.124774_bb0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature (London)"},{"key":"10.1016\/j.jchromb.2025.124774_bb0050","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jchromb.2025.124774_bb0055","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1038\/s41467-023-38108-1","article-title":"Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage","volume":"14","author":"Henderson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jchromb.2025.124774_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding Glycans","volume":"9","author":"Julien","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jchromb.2025.124774_bb0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/092986710790514499","article-title":"The GP120 molecule of HIV-1 and its interaction with T cells","volume":"17","author":"Yoon","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124774_bb0070","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jchromb.2025.124774_bb0075","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/infdis\/jiac041","article-title":"Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for human immunodeficiency virus prevention","volume":"226","author":"Mahomed","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jchromb.2025.124774_bb0080","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jchromb.2025.124774_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00796-21","article-title":"Enhanced ability of plant-derived PGT121 Glycovariants to eliminate HIV-1-infected cells","volume":"95","author":"Anand","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.jchromb.2025.124774_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042247","article-title":"Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in south African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial","volume":"10","author":"Mahomed","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jchromb.2025.124774_bb0095","doi-asserted-by":"crossref","first-page":"E653","DOI":"10.1016\/S2352-3018(23)00140-6","volume":"10","author":"Sobieszczyk","year":"2023","journal-title":"Lancet Hiv"},{"key":"10.1016\/j.jchromb.2025.124774_bb0100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2025.124774_bb0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2025.124774_bb0110","first-page":"15","article-title":"Pharmacokinetics of monoclonal antibodies and fc-fusion proteins, protein","volume":"9","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jchromb.2025.124774_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.709994","article-title":"Validation of a triplex pharmacokinetic assay for simultaneous quantitation of HIV-1 broadly neutralizing antibodies PGT121, PGDM1400, and VRC07-523-LS","volume":"12","author":"Wesley","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jchromb.2025.124774_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-2903-1_1","article-title":"Enzyme-linked immunosorbent assay: types and applications","volume":"2612","author":"Hayrapetyan","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jchromb.2025.124774_bb0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","article-title":"Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid","volume":"164","author":"Pluim","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2025.124774_bb0130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/FTD.0b013e3181b33da3","article-title":"An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab","volume":"31","author":"Ceze","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2025.124774_bb0135","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1021\/ac702115b","article-title":"Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry","volume":"80","author":"Hagman","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124774_bb0140","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.1021\/acs.analchem.2c01320","article-title":"Multiplex hybrid antigen-capture LC-MRM quantification in sera and nasal lining fluid of AZD7442, a SARS-CoV-2-targeting antibody combination","volume":"94","author":"Mu","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124774_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2014.03.013","article-title":"Preventing intense false positive and negative reactions attributed to the principle of ELISA to re-investigate antibody studies in autoimmune diseases","volume":"407","author":"Terato","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jchromb.2025.124774_bb0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.mex.2017.03.002","article-title":"An ELISA protocol to improve the accuracy and reliability of serological antibody assays","volume":"4","author":"Waritani","year":"2017","journal-title":"MethodsX"},{"key":"10.1016\/j.jchromb.2025.124774_bb0155","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1039\/D2AN01032A","article-title":"A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics","volume":"147","author":"Iwamoto","year":"2022","journal-title":"Analyst"},{"key":"10.1016\/j.jchromb.2025.124774_bb0160","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/ac800205s","article-title":"Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS\/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry","volume":"80","author":"Heudi","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124774_bb0165","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/ac7021234","article-title":"Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum","volume":"80","author":"Dubois","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124774_bb0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.aca.2018.02.040","article-title":"Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS\/MS","volume":"1019","author":"Chiu","year":"2018","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jchromb.2025.124774_bb0175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1039\/C9AY02087J","article-title":"Quantitative LC-MS\/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion","volume":"12","author":"Abe","year":"2019","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jchromb.2025.124774_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jchromb.2005.08.021","article-title":"A platform for high-throughput molecular characterization of recombinant monoclonal antibodies","volume":"826","author":"Bailey","year":"2005","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2025.124774_bb0185","doi-asserted-by":"crossref","first-page":"8776","DOI":"10.1021\/ac5019827","article-title":"Generic automated method for liquid chromatography-multiple reaction monitoring mass spectrometry based monoclonal antibody quantitation for preclinical pharmacokinetic studies","volume":"86","author":"Zhang","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124774_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1795492","article-title":"Development and validation of an LC-MS\/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab","volume":"12","author":"Schokker","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.jchromb.2025.124774_bb0195","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00545-16","article-title":"Mass spectrometry approaches for identification and quantitation of therapeutic monoclonal antibodies in the clinical laboratory","volume":"24","author":"Ladwig","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jchromb.2025.124774_bb0200","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1021\/jasms.0c00036","article-title":"Interlaboratory study for characterizing monoclonal antibodies by top-down and middle-down mass spectrometry","volume":"31","author":"Srzenti\u0107","year":"2020","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"2019","key":"10.1016\/j.jchromb.2025.124774_bb0205","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.4155\/bio-2019-0260","article-title":"White paper on recent issues in bioanalysis: chromatographic assays (part 1 - innovation in small molecules and Oligonucleotides & Mass Spectrometric Method Development Strategies for large molecule bioanalysis)","volume":"11","author":"Fandozzi","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2025.124774_bb0210","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2025.124774_bb0215","doi-asserted-by":"crossref","first-page":"9859","DOI":"10.1021\/ac402420v","article-title":"Fully validated LC-MS\/MS assay for the simultaneous quantitation of coadministered therapeutic antibodies in cynomolgus monkey serum","volume":"85","author":"Jiang","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124774_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462489","article-title":"A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry","volume":"1655","author":"Amrani","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2025.124774_bb0225","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.intimp.2015.07.007","article-title":"Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS\/MS","volume":"28","author":"Willrich","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jchromb.2025.124774_bb0230","doi-asserted-by":"crossref","first-page":"28566","DOI":"10.3390\/ijms161226120","article-title":"Parallel reaction monitoring: a targeted experiment performed using high resolution and high mass accuracy mass spectrometry","volume":"16","author":"Rauniyar","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jchromb.2025.124774_bb0235","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/rcm.7898","article-title":"Ultra-performance liquid chromatography\/multiple reaction monitoring mass spectrometry quantification of trastuzumab in human serum by selective monitoring of a specific peptide marker from the antibody complementarity-determining regions","volume":"31","author":"Russo","year":"2017","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2025.124774_bb0240","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.aca.2019.03.033","article-title":"A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug monitoring in patients with Crohn\u2019s disease","volume":"1067","author":"Willeman","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jchromb.2025.124774_bb0245","series-title":"Bioanalytical Method Validation and Study Stample Analysis M10","first-page":"59","author":"ICH","year":"2022"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225003289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225003289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:57:39Z","timestamp":1772891859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225003289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S1570023225003289"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124774","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS\/MS method for quantifying the HIV-1 broadly neutralizing antibody PGT 121.414.LS in human serum","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124774"}}